8-Aug-2022
Investor presentation, 8 August 2022 Investor presentation, 8 August 2022

8-Aug-2022
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS

29-Jul-2022
Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Activities/Appendix 4C Cash Flow Report

19-Jul-2022
Acadia submits Rett Syndrome New Drug Application to the FDA Acadia submits Rett Syndrome New Drug Application to the FDA

12-Jul-2022
Neuren commences Phase 2 trial of NNZ-2591 in Angelman syndrome Neuren commences Phase 2 trial of NNZ-2591 in Angelman syndrome

8-Jul-2022
Notification regarding unquoted securities - NEU Notification regarding unquoted securities - NEU

8-Jul-2022
Neuren appoints Chief Medical Officer in United States Neuren appoints Chief Medical Officer in United States

30-May-2022
Results of Meeting Results of Meeting

30-May-2022
AGM Chairman's Address & CEO Presentation AGM Chairman's Address & CEO Presentation

29-Apr-2022
Quarterly Activities/Appendix 4C Cash Flow Report Quarterly Activities/Appendix 4C Cash Flow Report